13 slides from Pharmaron Beijing Co., Ltd. Class A's earnings presentation, Apr 28, 2023
Slide 1: First Quarterly Results
Stock code: 300759.SZ Stock code: 3759.HK 2023 First Quarterly Results April, 2023
Slide 2: Disclaimer
Disclaimer The documents, opinions and mater ials presented in this presentation (the “ Document”) have been prepared by Phar maron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”) for use in presentations by the Company and does not constitute a recommendation regarding the securities of the
Slide 3: 1Q2023 Continued Strong Growth of Revenue & Profit
1Q2023 Continued Strong Growth of Revenue & Profit Revenue & Gross Profit Margin (GPM) Non-IFRS Adjusted Net Profit Attributable to Owners of the Company RMB mm RMB mm GPM 35.9% 36.5% 32.9% 35.6% +37.9% +29.5% +25.5% +20.3% 2,724 1,834 10,266 438 1,462 364 2,103 7,444 2021 2022 1Q2022 1Q2023 2021 20
Slide 4: 1Q2023 Non-IFRS Adjusted Net Profit Attributable to Owners of the Company
1Q2023 Non-IFRS Adjusted Net Profit Attributable to Owners of the Company RMB mm 1Q2022 1Q2023 Profit attributable to owners of the Company 249 348 Add: Share-based compensation expenses 16 60 Convertible Bonds related losses 34 39 Foreign exchange related losses/ (gains) 6 (1) Realized and unrealiz
Slide 5: Financial Data Highlights the Strong Resilience of Our Fully Integrated Platform
1Q2023 Financial Data Highlights the Strong Resilience of Our Fully Integrated Platform Segments Revenue Composition Global Customers Revenue Composition ROW, 2% Clinical Biologics and CGT Development Services, 4% Services, 14% NA revenue grew 34.7% China, 16% EU revenue grew 38.1% Small Molecule Eu
Slide 6: Solid Growth of Our Established Business Segments
1Q2023 Solid Growth of Our Established Business Segments Established Business Segments: excluding impact from Biologics and CGT Services and the addition of overseas small molecule manufacturing capacities, revenue and Non-IFRS net profit achieved solid growth ◼ Since 2021, we began to build Biologi
Slide 7: Laboratory Services
1Q2023 Laboratory Services Laboratory Services Revenue & GPM RMB mm GPM 43.3% 45.3% 42.0% 44.5% +38.5% 6,089 4,395 +29.7% 1,653 1,274 2021 2022 1Q2022 1Q2023 9,411 employees, increased by 185 in 1Q2023 Data are rounded to the nearest million. 1Q2022 and 1Q2023 financials are unaudited 7
Slide 8: CMC (Small Molecule CDMO) Services
1Q2023 CMC (Small Molecule CDMO) Services CMC (Small Molecule CDMO) Services Revenue & GPM RMB mm GPM 34.8% 34.6% 28.6% 32.9% +37.8% 2,407 1,746 +29.6% 598 462 2021 2022 1Q2022 1Q2023 4,003 employees, increased by 25 in 1Q2023 Data are rounded to the nearest million. 1Q2022 and 1Q2023 financials are
Slide 9: Clinical Development Services
1Q2023 Clinical Development Services Clinical Development Services Revenue & GPM RMB mm GPM 10.3% 11.5% 4.6% 14.0% +45.7% 1,394 956 +41.1% 374 265 2021 2022 1Q2022 1Q2023 3,631 employees, increased by 29 in 1Q2023 Data are rounded to the nearest million. 1Q2022 and 1Q2023 financials are unaudited 9
Slide 10: Biologics and CGT Services
1Q2023 Biologics and CGT Services Biologics and CGT Services Revenue & GPM RMB mm GPM 16.9% -2.2% 16.9% -11.7% +9.3% 351 321 +0.5% 95 95 2021 2022 1Q2022 1Q2023 622 employees, increased by 22 in 1Q2023 Data are rounded to the nearest million. 1Q2022 and 1Q2023 financials are unaudited 10
Slide 11: Expenses for the Period
1Q2023 Expenses for the Period Selling and Distribution Expenses as % of Total Revenue Administrative Expenses as % of Total Revenue (1) 13.4% 13.4% 13.3% 2.2% 2.2% 12.1% 11.3% 2.1% 2.0% 1.8% 2020 2021 2022 1Q2022 1Q2023 2020 2021 2022 1Q2022 1Q2023 Research and Development Cost as % of Total Revenu
Slide 12: 2023-2025 Outlook
2023-2025 Outlook The pursuit of health and longevity is eternal, and the global pharmaceutical markets will continue to develop Fully integrated service platforms can meet the needs of different kinds of customers, improving efficiency, reducing cost and providing flexibility We aim to double our r
Slide 13: Thank You
THANK YOU